everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...93949596979899100101102103...132133»
  • ||||||||||  PLX4720 / Daiichi Sankyo, everolimus / Generic mfg., Koselugo (selumetinib) / Merck (MSD), AstraZeneca
    Clinical, Journal:  BRAF status in personalizing treatment approaches for pediatric gliomas. (Pubmed Central) -  Jan 21, 2018   
    Application of these results to PLGG treatment must be exercised with caution because the dearth of PLGG models necessitated only a single patient-derived PLGG (BT40) in this study. Clin Cancer Res; 22(21); 5312-21.
  • ||||||||||  vatalanib (PTK787) / Novartis, Bayer
    Trial completion, Trial primary completion date, Combination therapy, Metastases:  Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jan 17, 2018   
    P1,  N=96, Completed, 
    N=50 --> 25 | Recruiting --> Terminated; Interim results suggested a concern for patient outcomes and safety Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
  • ||||||||||  carboplatin / Generic mfg., everolimus / Generic mfg., paclitaxel / Generic mfg.
    Trial primary completion date, Metastases:  Gastric Cancer RAD001 Study (clinicaltrials.gov) -  Jan 17, 2018   
    P1/2,  N=35, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009 Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  prednisone / Generic mfg., everolimus / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date, Metastases:  PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI (clinicaltrials.gov) -  Jan 16, 2018   
    P2,  N=8, Terminated, 
    Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Sep 2017 N=42 --> 8 | Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> May 2017
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene
    Trial primary completion date:  GSK1120212 Rollover Study (clinicaltrials.gov) -  Jan 12, 2018   
    P2,  N=250, Active, not recruiting, 
    N=42 --> 8 | Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> May 2017 Trial primary completion date: Nov 2017 --> Aug 2018
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial initiation date, Metastases:  Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Jan 10, 2018   
    P2,  N=13, Not yet recruiting, 
    Trial primary completion date: Dec 2017 --> Mar 2018 Initiation date: Dec 2017 --> Mar 2018
  • ||||||||||  veliparib (ABT-888) / AbbVie, Mekinist (trametinib) / Novartis, BeiGene, adavosertib (AZD1775) / AstraZeneca
    Trial suspension, PARP Biomarker, Metastases:  MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (clinicaltrials.gov) -  Jan 9, 2018   
    P2,  N=700, Suspended, 
    Initiation date: Dec 2017 --> Mar 2018 Recruiting --> Suspended
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Trial primary completion date, Metastases:  Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) -  Jan 5, 2018   
    P2,  N=108, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2022 --> Jun 2022 Trial primary completion date: Aug 2018 --> Aug 2019
  • ||||||||||  everolimus / Generic mfg.
    Trial primary completion date, Metastases:  Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium (clinicaltrials.gov) -  Jan 3, 2018   
    P2,  N=46, Active, not recruiting, 
    Trial primary completion date: Dec 2017 --> Jun 2018 Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  everolimus / Generic mfg.
    Preclinical, Journal:  Tunneling nanotube formation is stimulated by hypoxia in ovarian cancer cells. (Pubmed Central) -  Dec 31, 2017   
    When chemoresistant C200 and parent chemosensitive A2780 cells were co-cultured, chemoresistant cells displayed a higher likelihood of TNT formation to each other than to chemosensitive malignant or benign epithelial cells. Hypoxia-induced TNT formation represents a potential mechanism for intercellular communication in ovarian cancer and other forms of invasive refractory cancers.
  • ||||||||||  everolimus / Generic mfg., erlotinib / Generic mfg.
    Trial completion:  RAD001 and Erlotinib in Patients With Neuroendocrine Tumors (clinicaltrials.gov) -  Dec 29, 2017   
    P2,  N=17, Completed, 
    Trial primary completion date: Feb 2018 --> Feb 2020 Active, not recruiting --> Completed
  • ||||||||||  Herceptin (trastuzumab) / Roche, everolimus / Generic mfg.
    Clinical, Journal:  Statistical Controversies in Clinical Research: Statistical significance - too much of a good thing…. (Pubmed Central) -  Dec 25, 2017   
    A strict interpretation of this finding, based on complex "alpha splitting" rules to assess statistical significance, led to the conclusion that the benefit of everolimus was not statistically significant either overall or in the subset. We contend that this interpretation does not do justice to the data, and we argue that the benefit of everolimus in hormone receptor-negative breast cancer is both statistically compelling and clinically relevant.
  • ||||||||||  everolimus / Generic mfg.
    Trial completion, Phase classification:  Role of Everolimus in Highly Sensitized Patients (clinicaltrials.gov) -  Dec 19, 2017   
    P2,  N=20, Completed, 
    Trial primary completion date: Aug 2017 --> Nov 2014 Active, not recruiting --> Completed | Phase classification: PN/A --> P2
  • ||||||||||  everolimus / Generic mfg., bicalutamide / Generic mfg.
    Trial completion, Trial primary completion date:  RAD001 and Bicalutamide for Androgen Independent Prostate Cancer (clinicaltrials.gov) -  Dec 19, 2017   
    P2,  N=36, Completed, 
    Active, not recruiting --> Completed | Phase classification: PN/A --> P2 Terminated --> Completed | Trial primary completion date: Dec 2013 --> May 2012
  • ||||||||||  everolimus / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date, Metastases:  Phase II Study of RAD001 Head and Neck Cancer (clinicaltrials.gov) -  Dec 19, 2017   
    P2,  N=13, Terminated, 
    Terminated --> Completed | Trial primary completion date: Dec 2013 --> May 2012 N=50 --> 13 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2011 | N=50 --> 13 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2011 | N=50 --> 13 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2011
  • ||||||||||  anastrozole / Generic mfg., everolimus / Generic mfg., fulvestrant / Generic mfg.
    Trial suspension, Trial primary completion date, Metastases:  S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer (clinicaltrials.gov) -  Dec 18, 2017   
    P3,  N=825, Suspended, 
    N=50 --> 13 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2011 | N=50 --> 13 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2011 | N=50 --> 13 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Apr 2011 Active, not recruiting --> Suspended | Trial primary completion date: Sep 2017 --> May 2022 | Active, not recruiting --> Suspended | Trial primary completion date: Sep 2017 --> May 2022 | Active, not recruiting --> Suspended | Trial primary completion date: Sep 2017 --> May 2022
  • ||||||||||  Herceptin (trastuzumab) / Roche
    Trial completion, Enrollment change, Trial primary completion date, Metastases:  Phase II Trial of EVEROLIMUS  (clinicaltrials.gov) -  Dec 5, 2017   
    P2,  N=58, Completed, 
    N=306 --> 20 Active, not recruiting --> Completed | N=34 --> 58 | Trial primary completion date: Nov 2017 --> Jul 2017
  • ||||||||||  Review, Journal:  Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? (Pubmed Central) -  Nov 30, 2017   
    However, strategies aimed at reduction of disease relapse after reduced intensity conditioning allogeneic HCT are needed to improve the outcomes of this treatment. This review summarizes the current data on salvage chemotherapy and HCT strategies used to treat patients with relapsed Hodgkin lymphoma after prior autologous HCT.